DP-b99
Phase 3Small molecule
DP-b99 is one of 97 small molecule programs targeting Stroke. It is currently in Phase 3.
3
Indications
3
Total Trials
0
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1DP-b99
DD-Pharm Ltd.
Phase 3
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Direct Anticoagulant
BayerPreclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DP-b99. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DD-Pharm Ltd.